Answers are grounded in this paper and cite their sources.
Periodontitis is an infectious inflammatory disease of the supporting structures of the teeth. Resolvins are part of a large family of specialized pro-resolving lipid mediators that enhance active resolution of inflammation and return of inflammatory lesions to homeostasis. In this paper, we demonstrate that resolvin D2 (RvD2), a product of docosahexaenoic acid (DHA) metabolism, prevents alveolar bone loss in Porphyromonas gingivalis-induced experimental periodontitis. Investigations of the immune mechanism of RvD2 actions reveal that six weeks after infection, the gingiva of RvD2-treated mice exhibit decreased CD4+ T cells as well as lower RANKL expression levels and higher OPG expression levels. Systemically, RvD2 prevents chronic secretion of IFN-γ and rapidly restores IFN-α levels, without dampening the Porphyromonas gingivalis-specific immune response. In the gingiva, immediately after Porphyromonas gingivalis inoculation, RvD2 regulates the mRNA expression of IFN-ɣ, IL-1β, TNF-α and IL-10, hence contributing to maintaining local homeostasis. Moreover, RvD2 treatment reduces local neutrophil numbers, whereas pro-resolving macrophage counts were increased. These findings suggest that RvD2 resolves innate inflammatory responses, inhibiting systemic and gingival Th1-type adaptive responses that are known to mediate alveolar bone loss in this model.
No takes yet. Share an insight, caveat, or question.
Mizraji et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: